SecBot SecBot
PRESS-RELEASE ·Filed Mar 5, 2026

TNGX

Tango Therapeutics Sub, Inc
MIXED
Impact 6/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ◆ Mixed

The narrowing net loss and strong cash runway into 2028 reduce near-term dilution risk. However, the absence of recurring collaboration revenue and reliance on future clinical data (2026) make the stock sensitive to trial outcomes. Traders should monitor upcoming 2026 data readouts from vopimetostat combination trials as key catalysts.

DirectionMixed
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$16.83
T+0 close · Mar 5, 2026 · via day close
Latest settled
+37.25%
T+60 · $23.10
Vs SPY
+25.95%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 5 $16.83entry
  2. T+1 · 9mo ago +0.71%α +2.03% · $16.95
  3. T+5 · 8mo ago +1.90%α +4.14% · $17.15
  4. T+20 · 8mo ago +28.52%α +32.31% · $21.63
  5. T+60 · 6mo ago +37.25%α +25.95% · $23.10
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Tango Therapeutics reported financial results for Q4 and full year 2025, highlighted by a strong cash position of $343.1 million, reduced net losses year-over-year, and advancing its vopimetostat clinical program in pancreatic cancer. The company initiated a clinical supply agreement with Erasca and continues enrollment in combination trials with Revolution Medicines, with initial data expected in 2026. Leadership changes include CEO succession and expanded regulatory leadership.

Key Financial Metrics

Revenue
$0.00
-100.0% YoY
EPS
$-1.19

Key Facts

  • Cash, cash equivalents, and marketable securities totaled $343.1 million as of December 31, 2025, providing runway into 2028.
  • Collaboration revenue dropped to $0 in Q4 2025 from $5.4 million in Q4 2024; full-year 2025 collaboration revenue was $62.4 million vs. $30.0 million in 2024, driven by recognition of deferred revenue from Gilead.
  • Net loss narrowed to $101.6 million in 2025 from $130.3 million in 2024; Q4 2025 net loss was $38.7 million vs. $30.8 million in Q4 2024.
  • Vopimetostat pivotal study in 2L pancreatic cancer expected to start in 2026; initial combination data with RAS(ON) inhibitors anticipated in 2026.
  • CEO transition completed: Dr. Malte Peters succeeded founding CEO Dr. Barbara Weber, who became Executive Chair through 2026.

Financial Impact

Revenue declined sharply in Q4 2025 due to absence of collaboration income, but full-year revenue more than doubled due to one-time Gilead revenue recognition. R&D expenses decreased year-over-year due to discontinuation of TNG908 and TNG348 programs, contributing to improved net loss profile.

revenuenet losscash runwayR&D expenses

Risk Factors

  • Revenue is non-recurring and heavily reliant on past Gilead collaboration; no new major partnerships announced.
  • Clinical execution risk: pivotal trial initiation and data readouts are forward-looking and subject to delay.
  • Recent insider selling ($694K in 30 days) may signal caution among executives.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3250000

Track record

27 reports on TNGX

Performance horizon

3 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +29.28% at T+60 after the Jun 8, 2026 report. 5 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $24.22 Now $24.17 +0.21% settles Feb 16
  2. Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $24.50 Now $24.17 +1.35% settles Feb 12
  3. Nov 9, 20267d ago Press Release Neutral 5/10 Entry $22.74 Now $24.17 +6.29% settles Feb 5
  4. Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $21.50 Now $24.17 +12.42% settles Feb 4
  5. Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $20.87 Now $24.17 +15.81% settles Feb 3
  6. Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $23.17 Now $24.17 +4.32% settles Feb 1
  7. Nov 2, 202614d ago 144 Neutral 2/10 Entry $23.17 Now $24.17 +4.32% settles Feb 1
  8. Oct 23, 202624d ago 8-K Bullish 7/10 Entry $23.34 Now $24.17 +3.56% settles Jan 21
  9. Aug 11, 202613w ago 8-K Bearish 6/10 Entry $25.58 to $23.18 Now $24.17 +5.51% ▲ +9.38% +4.51% vs SPY
  10. Aug 11, 202613w ago 8-K Bullish 7/10 No price data
Showing 10 of 27

US Market Status

Market Closed · Opens in 9h 17m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 5, 2026